MeanderMC
Welcome,         Profile    Billing    Logout  
 7 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Smit, Egbert F
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT04648189: Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

Withdrawn
2
40
Europe
Cetuximab
The Netherlands Cancer Institute, Dutch Cancer Society
Lung Cancer, Surgery, Circulating Tumor Cell
09/22
09/22
STEREO, NCT04908956: Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC

Active, not recruiting
2
6
Europe, RoW
Osimertinib, Tagrisso, Stereotactic Body Radiation Therapy (SBRT)
ETOP IBCSG Partners Foundation, AstraZeneca
NSCLC Stage IV, EGFR Gene Mutation
03/26
03/26
NCT05601973 / 2021-002337-42: AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Recruiting
2
60
Europe, RoW
Amivantamab, Lazertinib, Zirabev
ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals
Non Small Cell Lung Cancer
03/26
09/26
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
12/24
12/24
TAS3351, NCT05765734: A Study of in NSCLC Patients With EGFRmt

Recruiting
1/2
200
Europe, Japan, US, RoW
TAS3351 oral administration
Taiho Oncology, Inc.
Non-Small Cell Lung Cancer
12/27
12/27
HAMLET, NCT02488850: Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC

Recruiting
N/A
40
Europe
Surgery, SABR
Erasmus Medical Center
Non-small Cell Lung Cancer
07/23
 
NCT03564197: 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

Recruiting
N/A
80
Europe
18F-PD-L1, tracer
The Netherlands Cancer Institute, Bristol-Myers Squibb
NSCLC Stage IV
12/23
12/24
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27
Dijkhorst-Oei, LT
DARE, NCT05669547: Dual Hormone Closed Loop in Type 1 Diabetes

Recruiting
N/A
240
Europe
dual hormone fully closed loop (DHFCL), Inreda AP (Inreda Diabetic BV)
UMC Utrecht, Dutch National Health Care Institute, Inreda Diabetic B.V.
Diabetes Mellitus, Type 1, Diabetes type1, Diabetes
10/25
01/26
Herder, Judith
NCT03564197: 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

Recruiting
N/A
80
Europe
18F-PD-L1, tracer
The Netherlands Cancer Institute, Bristol-Myers Squibb
NSCLC Stage IV
12/23
12/24

Download Options